Dallas, TX -- (SBWIRE) -- 08/29/2014 -- Hepatitis B is an inflammatory condition that occurs due to infection by hepatitis B virus. Hepatitis B virus is an enveloped virus that belongs to the family of hepadnavirus. It contains a circular genome with partially double-stranded DNA. The virus interferes with the normal functioning of the liver cells. Following the viral infection, the immune system is activated against virus and hepatocytes infected with viruses. This, in turn, leads to the inflammation of the liver. Extra-hepatic manifestations of hepatitis B include polyarteritis nodosa, Gianotti-Crosti syndrome, transient serum sickness-like syndrome, and membranous glomerulonephritis. Perinatal transmission of hepatitis B virus is the most common mode of infection spread. Age of a person at the time of infection and infecting dose of virus are important factors that determine the severity of acute or chronic hepatitis B. Most of the patients suffering from acute hepatitis B recover spontaneously without significant consequences. The chronic form of infection, in some cases, can progress up to cirrhosis and liver cancer. Hepatitis B infection can be prevented by immunization with hepatitis B vaccines.
The analysts forecast the Global Hepatitis B Vaccines market to grow at a CAGR of 4.00 percent over the period 2013-2018.
Covered in this Report
This report covers the present scenario and the growth prospects of the Global Hepatitis B Vaccines market for the period 2014-2018. To calculate the market size, the report considers revenue generated through the sales of various vaccines intended for active immunization against different serogroups of hepatitis B virus. In terms of composition, the Global Hepatitis B Vaccines market can be segmented into the following: Mono Vaccines and Combination Vaccines.
The Global Hepatitis B Vaccines Market 2014-2018 has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and the APAC and EMEA regions; it also covers the Global Hepatitis B Vaccines market landscape and its growth prospects in the coming years. The report includes a discussion of the key vendors operating in this market.
Key Regions
- Americas
- APAC
- EMEA
Key Vendors
- GlaxoSmithKline
- Merck
- Sanofi Pasteur
Buy a copy of report directly @ http://www.reportsnreports.com/purchase.aspx?name=296518.
Other Prominent Vendors
- Dynavax Technologies
- Janssen Pharmaceuticals
- LG Life Sciences
- Kaketsuken
- Shenzhen Kangtai Biological Products
Market Driver
- Increased Awareness about Hepatitis B Infection and Prevention
- For a full, detailed list, view our report
Market Challenge
- Inadequate Vaccine Coverage
- For a full, detailed list, view our report
Market Trend
- Combination Vaccines
- For a full, detailed list, view our report
Key Questions Answered in this Report
- What will the market size be in 2018 and what will the growth rate be?
- What are the key market trends?
- What is driving this market?
- What are the challenges to market growth?
- Who are the key vendors in this market space?
- What are the market opportunities and threats faced by the key vendors?
- What are the strengths and weaknesses of the key vendors?
Single User License of the Report is US $2500 for discount please contact us @ http://www.reportsnreports.com/contacts/discount.aspx?name=296518.